Fintel reports that on April 2, 2025, Leerink Partners upgraded their outlook for Compass Therapeutics (NasdaqCM:CMPX) from Market Perform to Outperform.
Analyst Price Forecast Suggests 419.11% Upside
As of March 19, 2025, the average one-year price target for Compass Therapeutics is $11.63/share. The forecasts range from a low of $4.04 to a high of $33.60. The average price target represents an increase of 419.11% from its latest reported closing price of $2.24 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Compass Therapeutics is 9MM, an increase of 1,008.82%. The projected annual non-GAAP EPS is -0.45.
What is the Fund Sentiment?
There are 174 funds or institutions reporting positions in Compass Therapeutics. This is an increase of 7 owner(s) or 4.19% in the last quarter. Average portfolio weight of all funds dedicated to CMPX is 0.09%, an increase of 114.52%. Total shares owned by institutions increased in the last three months by 9.52% to 106,575K shares. 
The put/call ratio of CMPX is 1.61, indicating a bearish outlook.
What are Other Shareholders Doing?
Orbimed Advisors holds 22,363K shares representing 16.17% ownership of the company. No change in the last quarter.
Blackstone Group holds 10,025K shares representing 7.25% ownership of the company. No change in the last quarter.
MPM Oncology Impact Management holds 8,568K shares representing 6.20% ownership of the company. In its prior filing, the firm reported owning 5,642K shares , representing an increase of 34.15%. The firm increased its portfolio allocation in CMPX by 13.25% over the last quarter.
Enavate Sciences GP holds 7,788K shares representing 5.63% ownership of the company.
Adage Capital Partners Gp, L.l.c. holds 5,995K shares representing 4.34% ownership of the company. In its prior filing, the firm reported owning 11,130K shares , representing a decrease of 85.66%. The firm decreased its portfolio allocation in CMPX by 57.96% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
